COMBIVENT RESPIMAT
SABASAMA SMI
Ipratropium bromide / Albuterol sulfate · Boehringer Ingelheim
Active Medication & Mechanism
- Ipratropium bromide SAMA20 mcg per actuation
Short-acting muscarinic antagonist (anticholinergic). Blocks vagal cholinergic tone at M3 receptors, reducing bronchospasm in COPD.
- Albuterol sulfate SABA100 mcg per actuation (albuterol base)
Short-acting beta2-adrenergic agonist. Relaxes bronchial smooth muscle by stimulating beta2-receptors, providing rapid bronchodilation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
20/100 mcg
1 inhalation four times a day (maximum 6 inhalations in 24 hours) → 80/400 mcg (standard); max 120/600 mcg
FDA Approved
Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.
Not Approved
Combivent Respimat is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
20/100 mcg 1 inhalation four times a day (maximum 6 inhalations in 24 hours) → 80/400 mcg (standard); max 120/600 mcg
COPD FDA Approved
Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.
Asthma Not Approved
Combivent Respimat is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Approved for as-needed acute use. 1 inhalation as needed; maximum 6 inhalations/24h. The SABA+SAMA combination provides bronchodilation for acute COPD symptoms.